Memory Aid by Intranasal Insulin in Diabetes (MemAID)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 289 participants.
Also called NCT02415556
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 289 participants
- Sponsor
- Registry
-
NCT02415556
-
- Other papers using this trial's data
- MemAID: Memory advancement with intranasal insulin vs. placebo in type 2 diabetes and control participants: a randomized clinical trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT02415556. Randomized; quadruple masking; primary purpose treatment. Start 2015-10-06 (actual); primary completion 2020-05-31 (actual). Results posted on 2021-09-17.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Memory Aid by Intranasal Insulin in Diabetes (MemAID)
- Acronym
- MemAID
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Regular Human Insulin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Collaborator
- Novo Nordisk A/S
- Collaborator
- Medtronic
- Collaborator
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Record details
- Record id
cardio:ct-nct02415556- Content hash
743bad261d80286ddde528cd04bfd90d8d91fca7e9986cbd1245a75115ea896a